The company has not filed an annual or quarterly report since its 20-F, filed Mar 26, 2018. Its latest SEC filing is a 15-12B from Jun 25, 2018.
20-F, filed Mar 26, 2018
The sections below describe the company as of the latest annual report.
Developed Nanobody-based drug candidates for a range of diseases, pursued selected programs toward commercialization, and partnered with pharmaceutical companies on others.
20-F, filed Mar 26, 2018
Pharmaceutical companies collaborated with Ablynx on Nanobody research and development programs.
20-F, filed Mar 26, 2018
Competes with Shire Pharmaceuticals, Valeant Pharmaceuticals, AstraZeneca, Gilead Sciences, Johnson & Johnson, Regeneron Pharmaceuticals, Novovax, GlaxoSmithKline, Crescendo Biologics, VHSquared, and Camel-IDs SV/SA
20-F, filed Mar 26, 2018With regard to our lead wholly owned product candidate, caplacizumab for the treatment of aTTP, there is no approved drug indicated for…View ↗
Loading...
